Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur L. Eugene ARNOLD |
Documents disponibles écrits par cet auteur (25)
Faire une suggestion Affiner la recherche
Positive Effects of Methylphenidate on Social Communication and Self-Regulation in Children with Pervasive Developmental Disorders and Hyperactivity / Laudan B. JAHROMI in Journal of Autism and Developmental Disorders, 39-3 (March 2009)
[article]
Titre : Positive Effects of Methylphenidate on Social Communication and Self-Regulation in Children with Pervasive Developmental Disorders and Hyperactivity Type de document : Texte imprimé et/ou numérique Auteurs : Laudan B. JAHROMI, Auteur ; Connie KASARI, Auteur ; David J. POSEY, Auteur ; Jaswinder GHUMAN, Auteur ; Erin KUSTAN, Auteur ; Louise RITZ, Auteur ; Elaine TIERNEY, Auteur ; Lisa S-Y. LEE, Auteur ; Andrea N. WITWER, Auteur ; Christopher J. MCDOUGLE, Auteur ; Michael G. AMAN, Auteur ; Benedetto VITIELLO, Auteur ; L. Eugene ARNOLD, Auteur ; Lawrence SCAHILL, Auteur ; James T. MCCRACKEN, Auteur Année de publication : 2009 Article en page(s) : p.395-404 Langues : Anglais (eng) Mots-clés : Methylphenidate Pervasive-developmental-disorders Hyperactivity Autism-spectrum-disorder Index. décimale : PER Périodiques Résumé : This report examined the effect of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity in a secondary analysis of RUPP Autism Network data. Participants were 33 children (29 boys) between the ages of 5 and 13 years who participated in a four-week crossover trial of placebo and increasing doses of methylphenidate given in random order each for one week. Observational measures of certain aspects of children’s social communication, self-regulation, and affective behavior were obtained each week. A significant positive effect of methylphenidate was seen on children’s use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state. The results go beyond the recent literature and suggest that methylphenidate may have positive effects on social behaviors in children with PDD and hyperactivity. En ligne : http://dx.doi.org/10.1007/s10803-008-0636-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=695
in Journal of Autism and Developmental Disorders > 39-3 (March 2009) . - p.395-404[article] Positive Effects of Methylphenidate on Social Communication and Self-Regulation in Children with Pervasive Developmental Disorders and Hyperactivity [Texte imprimé et/ou numérique] / Laudan B. JAHROMI, Auteur ; Connie KASARI, Auteur ; David J. POSEY, Auteur ; Jaswinder GHUMAN, Auteur ; Erin KUSTAN, Auteur ; Louise RITZ, Auteur ; Elaine TIERNEY, Auteur ; Lisa S-Y. LEE, Auteur ; Andrea N. WITWER, Auteur ; Christopher J. MCDOUGLE, Auteur ; Michael G. AMAN, Auteur ; Benedetto VITIELLO, Auteur ; L. Eugene ARNOLD, Auteur ; Lawrence SCAHILL, Auteur ; James T. MCCRACKEN, Auteur . - 2009 . - p.395-404.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 39-3 (March 2009) . - p.395-404
Mots-clés : Methylphenidate Pervasive-developmental-disorders Hyperactivity Autism-spectrum-disorder Index. décimale : PER Périodiques Résumé : This report examined the effect of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity in a secondary analysis of RUPP Autism Network data. Participants were 33 children (29 boys) between the ages of 5 and 13 years who participated in a four-week crossover trial of placebo and increasing doses of methylphenidate given in random order each for one week. Observational measures of certain aspects of children’s social communication, self-regulation, and affective behavior were obtained each week. A significant positive effect of methylphenidate was seen on children’s use of joint attention initiations, response to bids for joint attention, self-regulation, and regulated affective state. The results go beyond the recent literature and suggest that methylphenidate may have positive effects on social behaviors in children with PDD and hyperactivity. En ligne : http://dx.doi.org/10.1007/s10803-008-0636-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=695 Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems / Cristan A. FARMER in Journal of Autism and Developmental Disorders, 42-6 (June 2012)
[article]
Titre : Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems Type de document : Texte imprimé et/ou numérique Auteurs : Cristan A. FARMER, Auteur ; Luc LECAVALIER, Auteur ; Sunkyung YU, Auteur ; L. Eugene ARNOLD, Auteur ; Christopher J. MCDOUGLE, Auteur ; Lawrence SCAHILL, Auteur ; Benjamin L. HANDEN, Auteur ; Cynthia JOHNSON, Auteur ; Kimberly A. STIGLER, Auteur ; Karen E. BEARSS, Auteur ; Naomi SWIEZY, Auteur ; Michael G. AMAN, Auteur Année de publication : 2012 Article en page(s) : p.1037-1044 Langues : Anglais (eng) Mots-clés : Parent training Pervasive developmental disorder Autism Risperidone Predictor Moderator Index. décimale : PER Périodiques Résumé : The Research Units on Pediatric Psychopharmacology—Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The Home Situations Questionnaire (HSQ) and the Hyperactivity/Noncompliance subscale of the Aberrant Behavior Checklist were used as outcome measures. Candidate predictors and moderators included 21 demographics and baseline measures of behavior. Higher baseline HSQ scores predicted greater improvement on the HSQ regardless of treatment assignment, but no other predictors of outcome were observed. None of the variables measured in this study moderated response to PT. Antipsychotic medication plus PT appears to be equally effective for children with a wide range of demographic and behavioral characteristics. En ligne : http://dx.doi.org/10.1007/s10803-011-1338-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156
in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1037-1044[article] Predictors and Moderators of Parent Training Efficacy in a Sample of Children with Autism Spectrum Disorders and Serious Behavioral Problems [Texte imprimé et/ou numérique] / Cristan A. FARMER, Auteur ; Luc LECAVALIER, Auteur ; Sunkyung YU, Auteur ; L. Eugene ARNOLD, Auteur ; Christopher J. MCDOUGLE, Auteur ; Lawrence SCAHILL, Auteur ; Benjamin L. HANDEN, Auteur ; Cynthia JOHNSON, Auteur ; Kimberly A. STIGLER, Auteur ; Karen E. BEARSS, Auteur ; Naomi SWIEZY, Auteur ; Michael G. AMAN, Auteur . - 2012 . - p.1037-1044.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 42-6 (June 2012) . - p.1037-1044
Mots-clés : Parent training Pervasive developmental disorder Autism Risperidone Predictor Moderator Index. décimale : PER Périodiques Résumé : The Research Units on Pediatric Psychopharmacology—Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The Home Situations Questionnaire (HSQ) and the Hyperactivity/Noncompliance subscale of the Aberrant Behavior Checklist were used as outcome measures. Candidate predictors and moderators included 21 demographics and baseline measures of behavior. Higher baseline HSQ scores predicted greater improvement on the HSQ regardless of treatment assignment, but no other predictors of outcome were observed. None of the variables measured in this study moderated response to PT. Antipsychotic medication plus PT appears to be equally effective for children with a wide range of demographic and behavioral characteristics. En ligne : http://dx.doi.org/10.1007/s10803-011-1338-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=156 A Review of Complementary and Alternative Treatments for Autism Spectrum Disorders / Nicholas LOFTHOUSE in Autism Research and Treatment, (September 2012)
[article]
Titre : A Review of Complementary and Alternative Treatments for Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Nicholas LOFTHOUSE, Auteur ; Robert L. HENDREN, Auteur ; Elizabeth HURT, Auteur ; L. Eugene ARNOLD, Auteur ; Eric BUTTER, Auteur Année de publication : 2012 Article en page(s) : 21 p. Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Given the severe and chronic problems associated with Autism Spectrum Disorders (ASD) and the limitations of available treatments, there exists a large public health need for additional interventions. As more parents are inquiring about complementary and alternative treatments (CATs), both parents and practitioners require up-to-date information about them and whether and how to integrate them into treatment. After presenting data on CAT usage patterns for ASD, we review 13 ingestible (i.e., orally administered) and 6 noningestible (i.e., externally administered) CATs for ASD. For each CAT we briefly describe its definition; rationale for use; current research support, limitations, and future directions; safety issues; and whether we currently recommend, not recommend, or find it acceptable for the treatment of ASD. We conclude this paper with recommendations for future research and ten clinical recommendations for practitioners. En ligne : http://dx.doi.org/10.1155/2012/870391 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=201
in Autism Research and Treatment > (September 2012) . - 21 p.[article] A Review of Complementary and Alternative Treatments for Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Nicholas LOFTHOUSE, Auteur ; Robert L. HENDREN, Auteur ; Elizabeth HURT, Auteur ; L. Eugene ARNOLD, Auteur ; Eric BUTTER, Auteur . - 2012 . - 21 p.
Langues : Anglais (eng)
in Autism Research and Treatment > (September 2012) . - 21 p.
Index. décimale : PER Périodiques Résumé : Given the severe and chronic problems associated with Autism Spectrum Disorders (ASD) and the limitations of available treatments, there exists a large public health need for additional interventions. As more parents are inquiring about complementary and alternative treatments (CATs), both parents and practitioners require up-to-date information about them and whether and how to integrate them into treatment. After presenting data on CAT usage patterns for ASD, we review 13 ingestible (i.e., orally administered) and 6 noningestible (i.e., externally administered) CATs for ASD. For each CAT we briefly describe its definition; rationale for use; current research support, limitations, and future directions; safety issues; and whether we currently recommend, not recommend, or find it acceptable for the treatment of ASD. We conclude this paper with recommendations for future research and ten clinical recommendations for practitioners. En ligne : http://dx.doi.org/10.1155/2012/870391 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=201 Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study / B. S. G. MOLINA in Journal of Child Psychology and Psychiatry, 59-6 (June 2018)
[article]
Titre : Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study Type de document : Texte imprimé et/ou numérique Auteurs : B. S. G. MOLINA, Auteur ; A. L. HOWARD, Auteur ; J. M. SWANSON, Auteur ; A. STEHLI, Auteur ; J. T. MITCHELL, Auteur ; T. M. KENNEDY, Auteur ; J. N. EPSTEIN, Auteur ; L. Eugene ARNOLD, Auteur ; L. HECHTMAN, Auteur ; B. VITIELLO, Auteur ; B. HOZA, Auteur Article en page(s) : p.692-702 Langues : Anglais (eng) Mots-clés : Adhd Attention deficit disorder adolescence drug abuse Index. décimale : PER Périodiques Résumé : BACKGROUND: Inconsistent findings exist regarding long-term substance use (SU) risk for children diagnosed with attention-deficit/hyperactivity disorder (ADHD). The observational follow-up of the Multimodal Treatment Study of Children with ADHD (MTA) provides an opportunity to assess long-term outcomes in a large, diverse sample. METHODS: Five hundred forty-seven children, mean age 8.5, diagnosed with DSM-IV combined-type ADHD and 258 classmates without ADHD (local normative comparison group; LNCG) completed the Substance Use Questionnaire up to eight times from mean age 10 to mean age 25. RESULTS: In adulthood, weekly marijuana use (32.8% ADHD vs. 21.3% LNCG) and daily cigarette smoking (35.9% vs. 17.5%) were more prevalent in the ADHD group than the LNCG. The cumulative record also revealed more early substance users in adolescence for ADHD (57.9%) than LNCG (41.9%), including younger first use of alcohol, cigarettes, marijuana, and illicit drugs. Alcohol and nonmarijuana illicit drug use escalated slightly faster in the ADHD group in early adolescence. Early SU predicted quicker SU escalation and more SU in adulthood for both groups. CONCLUSIONS: Frequent SU for young adults with childhood ADHD is accompanied by greater initial exposure at a young age and slightly faster progression. Early SU prevention and screening is critical before escalation to intractable levels. En ligne : http://dx.doi.org/10.1111/jcpp.12855 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=363
in Journal of Child Psychology and Psychiatry > 59-6 (June 2018) . - p.692-702[article] Substance use through adolescence into early adulthood after childhood-diagnosed ADHD: findings from the MTA longitudinal study [Texte imprimé et/ou numérique] / B. S. G. MOLINA, Auteur ; A. L. HOWARD, Auteur ; J. M. SWANSON, Auteur ; A. STEHLI, Auteur ; J. T. MITCHELL, Auteur ; T. M. KENNEDY, Auteur ; J. N. EPSTEIN, Auteur ; L. Eugene ARNOLD, Auteur ; L. HECHTMAN, Auteur ; B. VITIELLO, Auteur ; B. HOZA, Auteur . - p.692-702.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 59-6 (June 2018) . - p.692-702
Mots-clés : Adhd Attention deficit disorder adolescence drug abuse Index. décimale : PER Périodiques Résumé : BACKGROUND: Inconsistent findings exist regarding long-term substance use (SU) risk for children diagnosed with attention-deficit/hyperactivity disorder (ADHD). The observational follow-up of the Multimodal Treatment Study of Children with ADHD (MTA) provides an opportunity to assess long-term outcomes in a large, diverse sample. METHODS: Five hundred forty-seven children, mean age 8.5, diagnosed with DSM-IV combined-type ADHD and 258 classmates without ADHD (local normative comparison group; LNCG) completed the Substance Use Questionnaire up to eight times from mean age 10 to mean age 25. RESULTS: In adulthood, weekly marijuana use (32.8% ADHD vs. 21.3% LNCG) and daily cigarette smoking (35.9% vs. 17.5%) were more prevalent in the ADHD group than the LNCG. The cumulative record also revealed more early substance users in adolescence for ADHD (57.9%) than LNCG (41.9%), including younger first use of alcohol, cigarettes, marijuana, and illicit drugs. Alcohol and nonmarijuana illicit drug use escalated slightly faster in the ADHD group in early adolescence. Early SU predicted quicker SU escalation and more SU in adulthood for both groups. CONCLUSIONS: Frequent SU for young adults with childhood ADHD is accompanied by greater initial exposure at a young age and slightly faster progression. Early SU prevention and screening is critical before escalation to intractable levels. En ligne : http://dx.doi.org/10.1111/jcpp.12855 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=363 The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder / Paul HERSCU in Journal of Autism and Developmental Disorders, 50-9 (September 2020)
[article]
Titre : The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Paul HERSCU, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Michael F. SNAPE, Auteur ; Joel D. BREGMAN, Auteur ; Lawrence GINSBERG, Auteur ; Robert HENDREN, Auteur ; Alexander KOLEVZON, Auteur ; Raun MELMED, Auteur ; Mark MINTZ, Auteur ; Nancy MINSHEW, Auteur ; Linmarie SIKICH, Auteur ; Ashraf ATTALLA, Auteur ; Brian KING, Auteur ; Thomas OWLEY, Auteur ; Ann CHILDRESS, Auteur ; Harry CHUGANI, Auteur ; Jean FRAZIER, Auteur ; Charles CARTWRIGHT, Auteur ; Tanya MURPHY, Auteur Article en page(s) : p.3233-3244 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Repetitive behavior Selective seretonin reuptake inhibitor Index. décimale : PER Périodiques Résumé : Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. There is limited evidence supporting its efficacy for repetitive behaviors (RRBs) in autistic spectrum disorder (ASD). We conducted a randomized controlled trial (RCT) of fluoxetine in 158 individuals with ASD (5-17 years). Following 14 treatment weeks (mean dose 11.8 mg/day), no significant differences were noted on the Children's Yale-Brown Obsessive Compulsive Scale; the proportion of responders was similar (fluoxetine: 36%; placebo: 41%). There were similar rates of AEs (e.g., insomnia, diarrhea, vomiting); high rates of activation were reported in both groups (fluoxetine: 42%; placebo: 45%). Overly cautious dosing/duration may have prevented attainment of a therapeutic level. Results are consistent with other SSRI RCTs treating RRBs in ASD.Trial Registration: clinicaltrials.gov Identifier: NCT00515320. En ligne : http://dx.doi.org/10.1007/s10803-019-04120-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430
in Journal of Autism and Developmental Disorders > 50-9 (September 2020) . - p.3233-3244[article] The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder [Texte imprimé et/ou numérique] / Paul HERSCU, Auteur ; Benjamin L. HANDEN, Auteur ; L. Eugene ARNOLD, Auteur ; Michael F. SNAPE, Auteur ; Joel D. BREGMAN, Auteur ; Lawrence GINSBERG, Auteur ; Robert HENDREN, Auteur ; Alexander KOLEVZON, Auteur ; Raun MELMED, Auteur ; Mark MINTZ, Auteur ; Nancy MINSHEW, Auteur ; Linmarie SIKICH, Auteur ; Ashraf ATTALLA, Auteur ; Brian KING, Auteur ; Thomas OWLEY, Auteur ; Ann CHILDRESS, Auteur ; Harry CHUGANI, Auteur ; Jean FRAZIER, Auteur ; Charles CARTWRIGHT, Auteur ; Tanya MURPHY, Auteur . - p.3233-3244.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-9 (September 2020) . - p.3233-3244
Mots-clés : Autism spectrum disorder Repetitive behavior Selective seretonin reuptake inhibitor Index. décimale : PER Périodiques Résumé : Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. There is limited evidence supporting its efficacy for repetitive behaviors (RRBs) in autistic spectrum disorder (ASD). We conducted a randomized controlled trial (RCT) of fluoxetine in 158 individuals with ASD (5-17 years). Following 14 treatment weeks (mean dose 11.8 mg/day), no significant differences were noted on the Children's Yale-Brown Obsessive Compulsive Scale; the proportion of responders was similar (fluoxetine: 36%; placebo: 41%). There were similar rates of AEs (e.g., insomnia, diarrhea, vomiting); high rates of activation were reported in both groups (fluoxetine: 42%; placebo: 45%). Overly cautious dosing/duration may have prevented attainment of a therapeutic level. Results are consistent with other SSRI RCTs treating RRBs in ASD.Trial Registration: clinicaltrials.gov Identifier: NCT00515320. En ligne : http://dx.doi.org/10.1007/s10803-019-04120-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=430 The Transition to Middle School is Associated with Changes in the Developmental Trajectory of ADHD Symptomatology in Young Adolescents with ADHD / Joshua M. LANGBERG in Journal of Clinical Child & Adolescent Psychology, 37-3 (July-September 2008)
PermalinkTime-dependent changes in positively biased self-perceptions of children with attention-deficit/hyperactivity disorder: A developmental psychopathology perspective / Betsy HOZA in Development and Psychopathology, 22-2 (May 2010)
PermalinkTrial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders / Lawrence SCAHILL in Journal of Autism and Developmental Disorders, 39-5 (May 2009)
PermalinkWhat Is the Value of Medication in ASC? / L. Eugene ARNOLD
PermalinkYoung adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression / James M. SWANSON in Journal of Child Psychology and Psychiatry, 58-6 (June 2017)
Permalink